<DOC>
	<DOCNO>NCT00048750</DOCNO>
	<brief_summary>The purpose study determine efficacy safety intravenous micafungin versus placebo prophylactic therapy invasive fungal infection patient intensive care unit consider high risk .</brief_summary>
	<brief_title>Comparative Study Micafungin ( FK463 ) Versus Placebo Prophylactic Antifungal Therapy ICU</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Inclusion Criteria Meets entry criterion high risk Exclusion Criteria Evidence active invasive fungal infection Received one dose systemic antifungal agent within 72 hour prior first dose study drug Known HIV positive CD4 count le 500 cells/mm3 Has lifeexpectancy le 72 hour moribund</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Anti-Fungal Therapy</keyword>
	<keyword>Preemptive Anti-Fungal Therapy</keyword>
	<keyword>Invasive Fungal Infection</keyword>
	<keyword>Micafungin</keyword>
	<keyword>ICU</keyword>
</DOC>